SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in September:

• 2024 Wells Fargo Healthcare Conference (Boston, MA)
  Fireside chat: Thursday, September 5, 2024, from 4:30 – 5:05 p.m. ET
  

• H.C. Wainwright 26th Annual Global Investment Conference (New York City)
  Fireside chat: Monday, September 9, 2024, from 9:30 – 10:00 a.m. ET
  

• Baird 2024 Global Healthcare conf (New York City) (will not be webcast)
  Presentation: Tuesday, September 10, 2024, from 9:50 – 10:20 a.m. ET
  

Unless otherwise specified, fireside chats will be webcast live and may be accessed via links in the Investors section of the Nurix website under Events and Presentations. The archived webcasts will be available on the Nurix website for 30 days after the event.

About Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit https://www.nurixtx.com.

Contacts:

Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
[email protected]

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
[email protected]